drugset / Trial / NCT06791070
A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Phase 2
Recruiting
20 enrolled
Fujian Medical University Union Hospital
First Affiliated Hospital of Wenzhou Medical University · collabFujian Provincial Hospital · collabQuanzhou First Hospital · collabZhangzhou Affiliated Hospital of Fujian Medical University · collabZhejiang Tumor Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if Disitamab Vedotin combined with Toripalimab works to treat advanced HER2-positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. The main questions it aims to answer are: Does this combination reduce tumor volume and delay disease progression? What medical problems do participants have when receving this combination? Participants will: Intravenous using this combination every 3 weeks until disease progression or intolerable adverse reactions occur. Visit the clinic once every 3 weeks for checkups and tests.
Timeline
- Start
- 2025-01
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |